Securities and Exchange Board of India Imposes Rs 22 Lakh Fine on Trimurti Drugs Pharma

Trimurti Drugs along with the persons acting in concerts were required to make a public announcement in terms of SAST Regulations. However, they failed to make such announcement.

Securities and Exchange Board of India (SEBI) imposed a fine of Rs 22 lakh on 13 promoters of Trimurti Drugs and Pharmaceuticals Ltd (TDPL) for their failure to make public announcement regarding acquisition of the company's shares.

A //SEBI-conducted probe found that TDPL Healthcare (India) Ltd, promoter entity of Trimurti Drugs, along with the persons acting in concerts (PACs) had acquired 22.25 lakh shares or 3.3 percent stake of Trimurti Drugs on January 22, 2010, through bulk deal.

Indian Drug Major Sun Pharma Settles Patent Litigation With Acorda Therapeutics
Indian drug major Sun Pharma has settled a patent litigation with US-based Acorda Therapeutics over Ampyra extended-release tablets.

TDPL Healthcare along with the PACs were required to make a public announcement in terms of SAST (Substantial Acquisition of Shares and Takeovers) Regulations as it was made through bulk deal. "However, they failed to make such announcement. Not making public announcement, on acquiring shares of TDPL on January 22, 2010, have not only failed to comply with the provisions of SAST Regulations but have also deprived the shareholders of the exit opportunity at the relevant time which has to be viewed seriously," SEBI noted.

Accordingly, SEBI has imposed a penalty of Rs 22 lakh on 13 noticees -- TDPL Healthcare, Arun Kumar Bhangadia, Arun Kumar Bhangadia HUF, Arvind Kumar Bhangadia, Arvind Kumar Devansh Bhangadia HUF, Gopikishan Arun Kumar Bhangadia HUF, Jyothi Bhangadia, Kantha Bhangadia, Kiran Bhangadia, Murlidhar Mutgi, Sripriya Mutgi, Sulochana Mutgi and Trimurti Advisory Services.

The fine should be paid jointly and severally, SEBI said in an order.

$750 AIDS Drug Introduced by a US Pharmaceutical Now Gets a $1 Competitor
Imprimis Pharmaceuticals is offering a customizable compounded formulations of the ingredients in the Daraprim drug that made headlines for over pricing.

During the period under review, these entities were in possession of 66.83 percent stake in Trimurti Drugs.

As per SEBI norm, no acquirer, who together with PACs holds, 55 percent or more but less than 75 percent stake in a target company, would purchase either by himself or through PACs any additional shares entitling him to exercise voting rights, unless he makes a public announcement about such transaction.

Pharmaceutical Companies Team Up to Push for Ethical Marketing Practices
For the first time ever, India's biggest pharma companies have come together to push for ethical marketing practices to clean up the industry's image.

Source-PTI

Uttar Pradesh Government Contemplates Special Initiatives for Pharma Sector
We are seriously considering facilitative provisions for pharma and drugs industry, said the principal secretary of the state industrial development department.